UPDATE: Raymond James Downgrades Sarepta Therapeutics (SRPT) to Market Perform as SRP-9001 Data Disappoint
Tweet Send to a Friend
(Updated - January 8, 2021 7:49 AM EST)
Raymond James analyst Danielle Brill downgraded Sarepta Therapeutics (NASDAQ: SRPT) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Raymond James analyst Danielle Brill downgraded Sarepta Therapeutics (NASDAQ: SRPT) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
